U.S. Markets close in 5 hrs 11 mins

Featured Company News - Ares Management Invests $1.45 Billion in DuPage Medical Group

Research Desk Line-up: Financial Engines Post Earnings Coverage

LONDON, UK / ACCESSWIRE / August 18, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Ares Management, L.P. (NYSE: ARES) ("Ares"), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=ARES. DuPage Medical Group ("DMG") announced on August 16, 2017, that it has entered into a strategic partnership with funds managed by the private equity group of Ares. The total value of the investment is $1.45 billion and the traction was completed on August 15, 2017. The investment will allow DMG to continue its plans for expansion and growth while maintaining independence of the physicians. For immediate access to our complimentary reports, including today's coverage, register for free now at:


Discover more of our free reports coverage from other companies within the Asset Management industry. Pro-TD has currently selected Financial Engines, Inc. (NASDAQ: FNGN) for due-diligence and potential coverage as the Company reported on August 08, 2017, its financial results for Q2 2017 which ended on June 30, 2017. Tune in to our site to register for a free membership, and be among the early birds that get our report on Financial Engines when we publish it.

At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on ARES; also brushing on FNGN. Go directly to your stock of interest and access today's free coverage at:



Transaction details

As per the strategic partnership between DMG and Ares, the influx of new investment will cover and support growth initiatives of all DMG businesses including DMG Practice Management Solutions (DMG's practice management Company) and Boncura Health Solutions (DMG's subsidiary). As per the terms of the strategic agreement, DMG's physician group, DuPage Medical Group Ltd, will continue to be 100% physician-owned-and-directed. They would also retain significant ownership interest in DMG Practice Management Solutions.

As part of the investment deal, Ares has also acquired Summit Partners' stake in DMG Practice Management Solutions after which Summit will exit as DMG's investment partner. DMG's CEO has clarified that the investment from Ares will greatly benefit DMG's patients as it would allow DMG to add more service lines, sites of care and increase the number of physicians. These additions will enable DMG to enhance its integrated outpatient delivery model and thereby power its initiatives to provide quality, efficiency, and access to patients.

Commenting on the investment from Ares, Mike Kasper, CEO of DMG, said:

"As DMG continues to grow in size and scale, it is critically important for our organization to remain independent and physician-led. Ares understands and supports our core mission, which is to maintain and enrich our patient-focused, doctor-directed culture. This partnership, which will particularly benefit our subsidiary Boncura, provides unprecedented access to capital and strategic backing for DMG's growth initiatives, such as population health, expansion into new geographies and additional service offerings. We believe this endeavor will ultimately enhance our ability to reach and treat patients."

Dr. Paul Merrick, President, and Chairman of DMG, added:

"We are extremely excited to welcome Ares as our partner, as DMG continues to grow to become the best group for all physicians and patients both within the Chicago area as well as nationally. Our partnership with Ares will allow us to maintain our physician-oriented culture and clinical autonomy."

About DuPage Medical Group

Downers Grove, Illinois based DMG was formed in 1999 with the merger of three healthcare groups from the western suburbs of Chicago. DMG is now one of the nation's leading and largest independent, multi-specialty physician groups. It has more than 600 primary care and specialty physicians in over 70 locations and handles more than 1.1 million patient visits annually. It provides a wide range of healthcare services to patients, utilizing leading-edge technology and techniques.

In June 2017, DMG announced its intention to acquire Northwest Health Care Associates, a multi-specialty clinic with locations serving Chicago's northwest suburbs. The acquisition is subject to completion of due diligence and final contract negotiations.

About Boncura Health Solutions

Boncura Health Solutions is a physician-owned and directed management services organization and a subsidiary of DuPage Medical Group. It was formed in 2011, and the Company aims to improve patient outcomes, efficiently manage at-risk populations to reduce unnecessaryhealthcare costs, deliver services in a cost-effective manner, and provides unique and convenient ways for patients, providers, and clients to access key support services. Its expertise allows hospitals and health systems, independent physician groups, and accountable care organizations to provide value-based care through efficient and intelligent administrative and clinical services. Today, Boncura serves more than 5,500 physician providers and partners, managing upwards of 350,000 lives, and processing more than seven million claims annually.

About Ares Management, L.P.

Los Angeles based Ares was founded in 1997. It is a publicly traded, leading global alternative asset manager with approximately $104 billion of assets under management (AUM) as of June 30, 2017. Its investments are divided into three main investment groups - Credit, Private Equity, and Real Estate. The Company has a disciplined investment philosophy that focuses on delivering compelling risk-adjusted investment returns throughout market cycles. Ares' growth as one of the largest alternative asset managers can be attributed to its experienced management team, focus on performance and high-quality investor base, which includes large pension funds, university endowments, sovereign wealth funds, banks and insurance Companies. The Company has 15 offices globally, including in the US, Europe, Asia and Australia.

Last Close Stock Review

At the close of trading session on Thursday, August 17, 2017, Ares Management's stock price marginally fell 0.84% to end the day at $17.75. A total volume of 42.58 thousand shares were exchanged during the session. The Company's shares are trading at a PE ratio of 24.76 and have a dividend yield of 5.18%. At Thursday's closing price, the stock's net capitalization stands at $3.79 billion.

Pro-Trader Daily:

Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charter holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.


For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: contact@protraderdaily.com

Phone number: (917) 341.4653

Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Pro-Trader Daily